Genetic Medicine of African Populations
Switch Therapeutics is a precision neuroscience biotechnology company founded in 2020 and based in San Francisco, California, developing biomarker-gated genetic medicines for central nervous system (CNS) diseases with high unmet need.
Verve Therapeutics is a Boston-based clinical-stage biotechnology company developing a pipeline of in vivo gene editing medicines designed to treat cardiovascular disease with a single, one-time treatment.
Soufflé Therapeutics is a genetic medicine company developing nucleic acid (siRNA) therapeutics that use proprietary cell-specific ligand-conjugation technology to target and deliver treatments to specific cell types.
Tessera Therapeutics is an early-stage life sciences company, founded and backed by Flagship Pioneering, pioneering Gene Writing — a new category of genetic medicine designed to write therapeutic messages into the genome to treat and potentially cure disease at its source.
Arrakis Therapeutics is a biopharmaceutical company pioneering RNA-targeted small molecules (rSMs) as a new class of genetic medicines. Its rSM platform enables orally available small molecules to bind RNA and modulate previously undruggable biological pathways, with an industrialized discovery toolkit spanning multiple modalities.
SanegeneBio is a clinical-stage biotechnology company developing RNAi (RNA interference) genetic medicines for metabolic, cardiovascular, and complement-mediated autoimmune diseases, including obesity.
Encoded Therapeutics is a clinical-stage biopharmaceutical company developing next-generation gene therapies for neurological disorders, translating precision genetic science into transformative genetic medicines.
African Genomics Short Course 2025 - Inaugural Iteration
BreezeBio (formerly GenEdit) is a South San Francisco genetic-medicine company developing precision-delivered nucleic acid therapies for autoimmune disease and oncology. Its proprietary NanoGalaxy platform uses non-lipid, hydrophilic polymer nanoparticles of tunable size, charge, and composition to selectively deliver DNA, RNA, and…
Patch Biosciences was a synthetic-biology and machine-learning company, founded in 2020 and based in New York, that built an AI platform for genetic sequence design — computationally engineering DNA "cargos" and regulatory elements to make gene and RNA therapies more effective, specific, and durable.
Scribe Therapeutics is a clinical-stage biotechnology company founded in 2018 and headquartered in Alameda, California, engineering CRISPR-based genetic medicines through its proprietary "CRISPR by Design" platform.
Arrakis Therapeutics is a clinical-stage biopharmaceutical company pioneering RNA-targeted small molecules (rSMs) — orally available small-molecule medicines designed to bind directly to RNA and reach targets long considered undruggable.
Beam Therapeutics is a biotechnology company pioneering precision genetic medicines through base editing, a technology that makes precise, predictable, and efficient single-base changes to the genome without cutting the DNA double helix.
Nava Therapeutics is a life-sciences company developing lipid nanoparticle (LNP) technology for delivering RNA therapeutics precisely to specific organs and cells, aiming to extend genetic medicines to previously untreatable diseases.
Bringing cutting-edge technologies in Genomics to African Scientists
Evox Therapeutics is an Oxford, United Kingdom based biotechnology company developing genetic medicines that expand the reach of gene therapy into the brain to transform the treatment landscape for severe neurodegenerative diseases.
Prime Medicine is a clinical-stage biotechnology company developing a new class of differentiated one-time curative genetic therapies built on Prime Editing, a versatile, precise, and efficient gene editing technology that can search and replace disease-causing genetic sequences at their precise location in the genome without causing double-strand…
SalioGen Therapeutics was a next-generation genetic medicine company, formerly based in Lexington, Massachusetts, developing gene therapies. It was surfaced as a portfolio company of d1-capital and added to the API Evangelist network as a biotech stub.
Dyno Therapeutics is an AI and biotechnology company building high-performance gene delivery technologies to unlock the potential of next-generation genetic medicine. Using its CapsidMap platform, which combines machine learning with high-throughput in vivo measurement, Dyno designs novel adeno-associated virus (AAV) capsids with improved tissue…
Add a description, image, and links to the genetic-medicine topic page so that developers can more easily learn about it.
To associate your repository with the genetic-medicine topic, visit your repo's landing page and select "manage topics."